[O7] Oral Session 7　Gastrointestinal Cancer 2（Lower GI Tract-Colorectal Cancer 1）
【E】

[O7-2] FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type mCRC: the subgroup-analysis of DEEPER trial (JACCRO CC-13)

^○Taichi Yabuno¹, Akihito Tsuji², Takuya Tokunaga³, Satoshi Yuki⁴, Toshihiro Kudo⁵, Naoki Mashita⁶, Koji Ando⁷, Nobumichi Takeuchi⁸, Tomomi Kashiwada⁹, Masato Kataoka¹⁰, Mitsugu Kochi¹¹, Tamotsu Sagawa¹², Masahito Kotaka¹³, Yutaro Kubota¹⁴, Yu Sunakawa¹⁵, Takashi Sekikawa¹⁶, Masato Nakamura¹⁷, Masahiro Takeuchi¹⁸, Wataru Ichikawa¹⁶, Masashi Fujii¹⁹ (1.Department of Gastrointestinal Surgery, Yokohama Municipal Citizen's Hospital, 2.Department of Clinical Oncology, Faculty of Medicine, Kagawa University, 3.Department of Surgery, Tokushima University, 4.Department of Gastroenterology and Hepatology, Hokkaido University Hospital, 5.Department of Clinical Oncology, Osaka International Cancer Institute, 6.Department of Surgery, Konan Kosei Hospital, 7.Department of Surgery and Science, Kyushu University, 8.Department of Clinical Oncology, Ina Central Hospital, 9.Department of Clinical Oncology, Saga Prefectural Hospital Koseikan, 10.Department of Surgery, National Hospital Organization Nagoya Medical Center, 11.Department of Digestive Surgery, Nihon University Itabashi Hospital, 12.Division of Gastroenterology, National Hospital Organization Hokkaido Cancer Center, 13.Gastrointestinal Cancer Center, Sano Hospital, 14.Department of Clinical Oncology, Showa University Hospital, 15.Department of Clinical Oncology, St. Marianna University School of Medicine, 16.Division of Medical Oncology, Showa University Fujigaoka Hospital, 17.Aizawa Comprehensive Cancer Center, Aizawa Hospital, 18.Graduate School of Mathematical Sciences, The University of Tokyo, 19.Department of Digestive Surgery, Nihon University School of Medicine)